Cemiplimab-induced cytokine-release syndrome: second case reported and review of the literature.

Immunotherapy has become an increasingly important part of cancer treatment. This treatment has many side effects, mainly linked with immune system activation. Cytokine-release syndrome is one of the rare complications; it causes hyperthermia, hypotension and biological inflammation. Diagnosis of this syndrome is critical, as it can be life threatening. Diagnosis and early management, including stopping immunotherapy and administering corticosteroids and, in some cases, anti-IL- 6, leads to a favorable outcome in the majority of cases. The authors report the second case of cytokine-release syndrome after cemiplimab infusion used in the first-line treatment of cutaneous unresectable squamous-cell carcinoma.